GLOBUS MEDICAL INC — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Globus Medical reported Q2 2026 net sales of $789.6 million, up 5.9% YoY (5.6% constant currency). GAAP diluted EPS was $1.10, down 26.2% due to absence of prior-year $110.5M Nevro bargain purchase gain. Non-GAAP diluted EPS was $1.34, up 55.8% YoY, reflecting margin expansion of 200bps, strong US Spine growth of 7%, and International Spine growth of 14% as-reported. Company reaffirmed full-year 2026 revenue guidance of $3.18–$3.22B and raised non-GAAP EPS guidance to $4.95–$5.05 from $4.70–$4.80.
Why this rating
Solid operational performance with raised guidance materially above expectations. 200bps margin expansion and 55.8% non-GAAP EPS growth demonstrate synergy realization post-Nevro. Relative to $6.6B market cap, $789.6M quarterly revenue and upside guidance revision are meaningful but represent ongoing execution vs. transformational event.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.